Day: June 14, 2021

SOUTH SAN FRANCISCO, Calif., June 14, 2021 (GLOBE NEWSWIRE) — Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced that Chief Executive Officer Paul Hastings has been elected as the Chair of the Biotechnology Innovation Organization (BIO) Board of Directors for the 2021-2022 term. “Paul is a true biotech pioneer with an incredible journey first as a patient, then as a patient advocate, a biotech innovator, CEO, a BIO committee organizer and now as the new Chair of BIO’s Board of Directors,” said Ali Behbahani, MD, co-founder and Chair of Nkarta’s Board of Directors. “We applaud Paul’s election. We have witnessed firsthand the power of Paul’s vision at Nkarta and look forward to seeing him help support the broader biotech industry as it...

Angela Strand, Lead Independent Director, appointed Executive Chairwoman Becky Roof, appointed Interim CFO CEO Steve Burns and CFO Julio Rodriguez resign from Company LORDSTOWN, Ohio, June 14, 2021 (GLOBE NEWSWIRE) — Lordstown Motors Corp. (Nasdaq: RIDE), (“Lordstown Motors” or the “Company”), a leader in electric light duty trucks focused on the commercial fleet market, today announced several changes to its executive management team as the Company begins to transition from the R&D and early production phase to the commercial production phase of its business. To that end, Lordstown Motors Lead Independent Director Angela Strand has been appointed Executive Chairwoman of the Company, and will oversee the organization’s transition until a permanent CEO is identified, and Becky Roof, will serve as Interim Chief Financial Officer....

The Netherlands Grants AIM a Patent for Ampligen as a Cancer Therapy for Use in Combination with Checkpoint Blockade Inhibitors OCALA, Fla., June 14, 2021 (GLOBE NEWSWIRE) — AIM ImmunoTech Inc. (NYSE American: AIM) today announced that its drug Ampligen has been featured in a publication containing state-of-the-art methodologies in the peer-reviewed medical journal Cancers as a potential treatment option for cancer patients who are infected with SARS-CoV-2. The study’s authors stated that Ampligen has the potential to reduce the severity of the deadly respiratory disease COVID-19, which has so far caused more than 3.7 million deaths globally. According to the data presented in the publication, “Rintatolimod [Ampligen] activated the innate and the adaptive immune systems by activating a cascade of actions in human pancreatic cancer...

VANCOUVER, British Columbia, June 14, 2021 (GLOBE NEWSWIRE) — Ceylon Graphite Corp. (“Ceylon Graphite”) (TSX-V: CYL) (OTC: CYLYF) (FSE: CCY) is pleased to announce that it has acquired an exclusive global licence from Cambridge Advanced Materials & Innovation (“CAMI”). The licence pertains to a method of producing high quality few-layer graphene (“FLG”) and derivatives by exfoliation of high grade vein graphite produced by Ceylon Graphite (“The Technology”). This is a low-energy process which results in high-yield, few layer graphene products. This industrial process is already fully designed for large volume production, and is scalable, with modules added as demand increases. Upon completion of the licence agreement, Ceylon Graphite has gained full access to all intellectual property surrounding The Technology and know-how....

First FXR agonist trial to demonstrate no discontinuations due to AEs, including pruritus, and both a differentiated pruritus and lipid profile in patients with NASH First 12-week controlled trial in patients with NASH to show significant improvements in corrected T1 (cT1), an imaging marker of liver inflammation and fibrosis linked to clinical outcomes Terns plans to initiate first NASH trial of an FXR agonist (TERN-101) in combination with a THR-β agonist (TERN-501) in 1H22 Company to host conference call and webcast at 8:30 a.m. ET today FOSTER CITY, Calif., June 14, 2021 (GLOBE NEWSWIRE) — Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic...

– Profitable aftermarket business with capabilities for hydrogen and renewable natural gas replacement parts – MONTREAL, June 14, 2021 (GLOBE NEWSWIRE) — Xebec Adsorption Inc. (TSX: XBC) (“Xebec”), a global provider of clean energy solutions, is pleased to announce that on June 11, 2021, it has closed the acquisition of all the outstanding shares of United Kingdom based Tiger Filtration (“TFL”). The acquisition of TFL will provide Xebec with a very profitable and recurring aftermarket manufacturing business for elements and filters. TFL’s R&D capabilities will also allow for expansion of its product portfolio to include filtration products for hydrogen and renewable natural gas (RNG). Founded in 2004 by former Walker Filtration employees (Bob Thompson, Gary Ashton and Matthew Rowe), TFL has gained worldwide recognition...

EDMONTON, Alberta, June 14, 2021 (GLOBE NEWSWIRE) — Bitcoin Well Inc. (formerly Red River Capital Corp.) (the “Company”) (TSXV: XBT.P) announces today that it has completed its previously announced arm’s length qualifying transaction (the “Transaction”) with 1739001 Alberta Ltd. (o/a Bitcoin Well) (“Old Bitcoin Well”) along with the conversion of the subscription receipts (the “Subscription Receipts”) issued in connection with the Company’s previously announced $7.0 million private placement offering (the “Offering”) led by Canaccord Genuity Corp. “We are absolutely ecstatic to have completed the Transaction, which kicks off the next phase of our continued evolution as we become a publicly traded company,” said Adam O’Brien, CEO of the Company. “In anticipation of this milestone, we have already established governance protocols...

–Interim report completed by ALX for a standard ongoing non-clinical safety study  –Based on the safety study results, the FDA has lifted a previously set partial clinical hold and cap on patient enrollment in ASPEN-03 and ASPEN-04 –The first of two distinct randomized Phase 2 head and neck cancer studies in collaboration with Merck has been initiated; enrollment in ASPEN-03 is ongoing BURLINGAME, Calif., June 14, 2021 (GLOBE NEWSWIRE) — ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced updates on its ALX148 Phase 2 studies in patients with advanced head and neck squamous cell carcinoma (“HNSCC”). The U.S. Food and Drug Administration (“FDA”) informed ALX Oncology that it reviewed its...

NEW YORK, June 14, 2021 (GLOBE NEWSWIRE) — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases, today reported that ANAVEX®2-73 (blarcamesine) and ANAVEX®3-71 (AF710B) are featured in a new peer-reviewed publication in the journal of Expert Opinion on Therapeutic Targets, titled “The emerging role of the sigma-1 receptor in autophagy: Hand-in-hand targets for the treatment of Alzheimer’s”.1 Scientific Paper Highlights:Sigma-1 receptor (SIGMAR1)’s expression increases with age, however in Alzheimer’s disease (AD) it decreases The decrease...

PHILADELPHIA, June 14, 2021 (GLOBE NEWSWIRE) — Amicus Therapeutics (Nasdaq: FOLD), today announced the election and appointment of Eiry W. Roberts, M.D. to its Board of Directors. Dr. Roberts is an esteemed drug developer who brings approximately 30 years of pharmaceutical industry experience to the Company’s Board of Directors, having served in various leadership positions throughout her career and bringing extensive experience advancing therapies across all phases of drug development. John F. Crowley, Chairman and Chief Executive Officer of Amicus Therapeutics, Inc., stated, “On behalf of our Board of Directors, I am pleased to announce the appointment of Dr. Eiry Roberts to the Amicus Board. Eiry’s extensive background in clinical research and drug development across a diverse range of therapeutic areas adds immense value to...